3Brar SS,Hirernath S,Dangas G,et al.Sodium Bicarbonate for the Prevention of Contrast Induced-Acute Kidney Injury:A Systematic Review and Meta-analysis.CJASN,2009,4(10):1584-1592.
4Hoste EAJ,De Waele JJ,Gevaert SA,et al.Sodium bicarbonate for prevention of contrast-induced acute kidney injury:a systematic review and meta-analysis.Nephrology Dialysis Transplantation,2010,25(3):747-758.
5Lindsay J,Apple S,Pinnow E,et al.Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine.Catheterization and Cardiovascular Interventions,2003,59(3):338-343.
6Marenzi G,Lauri G,Assanelli E,et al.Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction.JACC,2004,44(9):1780-1785.
7Drager L,Andrade L,Barros de Toledo J,et al.Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy:decrease in oxidant stress-mediated renal tubular injury.Nephrology Dialysis Transplantation,2004,19(7):1803.
8Marenzi G,Assanelli E,Marana I,et al.N-acetylcysteine and contrast-induced nephropathy in primary angioplasty.NEJM,2006,354(26):2773.
9Thiele H,Hildebrand L,Schirdewahn C,et al.Impact of High-Dose N-Acetylcysteine Versus Placebo on Contrast-Induced Nephropathy and Myocardial Reperfusion Injury in Unselected Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention The LIPSIA-N-ACC (Prospective,Single-Blind,Placebo-Controlled,Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial.JACC,2010,55(20):2201-2209.
10Carbonell N,Sanjuan R,Blasco M,et al.N-acetylcysteine:Short-Term Clinical Benefits After Coronary Angiography in High-Risk Renal Patients.Revista Espanola De Cardiologia,2010,63(1):12-19.
1Navaneethan SD, Hegbrant J, Strippoli GF. Role of statins inpreventing adverse cardiovascular outcomes in patients with chronickidney disease [J]. Curr Opin Nephrol Hypertens,2011,20(2):146-152.
2Deshmukh A, Mehta JL. Statins and renal disease: friend or foe[J]. Curr Atheroscler Rep,2011,13( 1) :57-63.
3Ridker PM, MacFadyen J, Cressman M, et al. Efficacy of rosuv-astatin among men and women with moderate chronic kidneydisease and elevated high-sensitivity C-reactive protein : asecondary analysis from the JUPITER ( Justification for the Use ofStatins in Prevention-an Intervention Trial EvaluatingRosuvastatin) trial [J]. J Am Coll Cardiol, 2010, 55 ( 12 ) : 1266-1273.